Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 8Sarcoma 2Neoplasms 2Neoplasm Metastasis 2Multi-centric Castleman's Disease 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphadenopathy 1Liposarcoma 1Leiomyosarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1HIV Infections 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Endometrial Neoplasms 1

Interventions

Fulvestrant 34Specimen Handling 31Letrozole 30Paclitaxel 23pembrolizumab 19Carboplatin 19ribociclib 18exemestane 18Capecitabine 17Trastuzumab 16Tamoxifen 16Magnetic Resonance Spectroscopy 16palbociclib 15Anastrozole 15Biopsy 14trastuzumab deruxtecan 13abemaciclib 13pertuzumab 11Radiotherapy 11Cyclophosphamide 9inavolisib 8elacestrant 8olaparib 7Taxes 7Standard of Care 7Radiation 7Mastectomy, Segmental 7Goserelin 7130-nm albumin-bound paclitaxel 7giredestrant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × liposomal doxorubicin × 30 days × Clear all
NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,000 enrolled
Breast

Breast Neoplasms

NCT06312176 2026-05-22

MK-2870-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,200 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡